US 11,717,559 B2
Interleukin 15 protein complex and use thereof
Xiangdong Qu, Shanghai (CN); Xin Ye, Shanghai (CN); Qiyue Hu, Shanghai (CN); Dongbing Cui, Shanghai (CN); Weikang Tao, Shanghai (CN); Lianshan Zhang, Shanghai (CN); and Piaoyang Sun, Jiangsu (CN)
Assigned to Jiangsu Hengrui Medicine Co., Ltd.; and Shanghai Hengrui Pharmaceutical Co., Ltd.
Filed by Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
Filed on Dec. 21, 2020, as Appl. No. 17/129,100.
Application 17/129,100 is a division of application No. 15/537,107, granted, now 10,905,743, previously published as PCT/CN2015/094780, filed on Nov. 17, 2015.
Claims priority of application No. 201410799889.4 (CN), filed on Dec. 19, 2014.
Prior Publication US 2021/0106655 A1, Apr. 15, 2021
Int. Cl. C12N 15/62 (2006.01); A61K 38/20 (2006.01); C07K 14/54 (2006.01); A61P 35/00 (2006.01); C07K 14/715 (2006.01); C07K 19/00 (2006.01); A61P 37/04 (2006.01); A61P 37/02 (2006.01); A61P 31/00 (2006.01); A61P 17/00 (2006.01); A61P 19/02 (2006.01); A61P 1/00 (2006.01); A61P 29/00 (2006.01); A61K 47/64 (2017.01); C07K 16/30 (2006.01)
CPC A61K 38/2086 (2013.01) [A61K 38/20 (2013.01); A61P 1/00 (2018.01); A61P 17/00 (2018.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); A61P 37/04 (2018.01); C07K 14/5443 (2013.01); C07K 14/7155 (2013.01); C07K 19/00 (2013.01); C12N 15/62 (2013.01); A61K 47/642 (2017.08); A61K 2300/00 (2013.01); C07K 16/30 (2013.01); C07K 2319/30 (2013.01)] 15 Claims
 
1. One or more nucleic acids encoding an IL-15 protein complex comprising a soluble fusion protein (I) and a soluble fusion protein (II), wherein:
the soluble fusion protein (I) comprises an IL-15 polypeptide; and the soluble fusion protein (II) comprises an IL-15Rα polypeptide;
wherein the soluble fusion protein (I) comprises an amino acid Cys substitution at a position corresponding to residue Q48, V49, L52 or E53 of the IL-15 polypeptide having the amino acid sequence of SEQ ID NO: 1, and the soluble fusion protein (II) comprises an amino acid Cys substitution at a position corresponding to residue A37, G38, S40 or L42 of the IL-15Rα polypeptide having the amino acid sequence of SEQ ID NO: 4, and a disulfide bond is formed by Cys residues of the soluble fusion protein (II) and the soluble fusion protein (I).